Capital One (COF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 22. On t ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Lockheed Martin (LMT) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 22, might help the stock move higher if these key numbers are better than expectation ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Northrop Grumman (NOC) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 22. On ...

Wall Street expects a year-over-year decline in earnings on lower revenues when NVR (NVR) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lowe ...

Core Viewpoint - GE Aerospace is expected to report strong second-quarter 2025 results, with earnings projected at $1.43 per share and revenues at $9.7 billion, reflecting year-over-year growth of 19.2% and 17.9% respectively [1][6]. Earnings Estimates - The earnings estimate for the current quarter has increased by $0.01 over the past week, indicating a positive trend [2]. - The consensus estimate for quarterly revenues is $9.7 billion, showing a year-over-year growth of 17.9% [1][6]. Earnings Surprise History - GE Aerospace has consistently outperformed earnings estimates, with an average surprise of 18% over the last four quarters [2]. Earnings Prediction - The company has a positive Earnings ESP of +4.94% and a Zacks Rank of 1 (Strong Buy), suggesting a high likelihood of an earnings beat [3]. Segment Performance - The Commercial Engines & Services segment is expected to generate revenues of $7.43 billion, reflecting a sequential growth of 6.5% due to strong demand for its engine platforms [4]. - The Defense & Propulsion Technologies segment is anticipated to achieve revenues of $2.57 billion, indicating a 10.5% sequential increase, driven by rising defense budgets and demand for commercial air travel [5]. Operational Investments - GE has been investing in expanding and upgrading manufacturing facilities in the U.S., which is expected to enhance operational capacity and meet increased demand [6][7]. Portfolio Restructuring - The completion of the Vernova spin-off has allowed GE to focus on its core aerospace business, improving operational focus and financial flexibility [8]. Cost Challenges - High costs and operating expenses from restructuring activities and supply chain challenges may impact performance [9]. Stock Performance - GE Aerospace's shares have increased by 43.8% over the past three months, outperforming the Zacks Aerospace-Defense industry and the S&P 500 [10]. Valuation Metrics - The company is trading at a forward P/E ratio of 43.47X, which is higher than the industry average of 27.51X, indicating potential vulnerability to market sentiment shifts [12]. Investment Outlook - The robust portfolio and strength in aerospace and defense markets are expected to drive performance, with organic revenue growth projected in the low-double-digit range for 2025 [15]. - The company's focus on reducing operational costs and improving margins is expected to enhance long-term cash flow [16]. - Given the positive analyst sentiment and growth prospects, the current market conditions may be favorable for potential investors [18].

Core Insights - Novartis AG is set to report its second-quarter 2025 results on July 17, with revenue expectations at $14.04 billion and earnings at $2.38 per share [1] - The company has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 7.12% [1] Earnings Prediction - The Earnings ESP for Novartis is -0.28%, indicating a lower likelihood of an earnings beat this quarter [3] - The company currently holds a Zacks Rank of 2 (Buy) [3] Growth Drivers - Novartis operates in four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology following the spin-off of the Sandoz business [4] - Key products driving growth include Entresto, Kisqali, Kesimpta, Leqvio, and Scemblix, with strong sales expected in Q2 [4][8] Product Performance - Entresto's sales are estimated at $2.3 billion, benefiting from increased demand in China and Japan [5] - Kisqali's sales are projected at $1 billion, driven by its recognition in breast cancer treatment [6][7] - Kesimpta's sales are also expected to reach $1 billion, reflecting increased demand [7] - Cosentyx is anticipated to generate sales of $1.73 billion, supported by recent launches and volume growth [9] - Leqvio's sales estimates are $284 million, indicating strong growth in cholesterol management [10] - Pluvicto's sales are projected at $410 million, bolstered by FDA approval for expanded use [11] - Scemblix continues to see growth in chronic myeloid leukemia treatment, with strong demand expected [12] Recent Developments - Novartis acquired Regulus Therapeutics for $0.8 billion, adding farabursen to its pipeline, which targets autosomal dominant polycystic kidney disease [14] - Year-to-date, Novartis shares have increased by 27.3%, significantly outperforming the industry average of 1.8% [15]

Core Viewpoint - U.S. Bancorp (USB) is expected to report year-over-year increases in revenues and earnings for Q2 2025, benefiting from lower expenses and higher non-interest income [1] Group 1: Financial Performance Expectations - The company anticipates net interest income (NII) for Q2 2025 to be between $4.1 billion and $4.2 billion, with a consensus estimate of $4.01 billion, reflecting a marginal increase from the previous quarter [2][8] - The consensus estimate for total revenues in Q2 2025 is $7.06 billion, indicating a rise of 3.3% from the year-ago figure [13] - The Zacks Consensus Estimate for average earning assets is $611.2 million, suggesting a slight sequential increase [4] Group 2: Non-Interest Income and Trading Activity - Non-interest income is projected to rise by 3.3% due to gains in trading, mortgage, and card revenues, with total non-interest income estimated at $2.93 billion [9][8] - Trading volumes in equity derivatives and corporate bonds have increased, with the consensus estimate for commercial product revenues at $391 million, reflecting a 2.4% increase from the prior quarter [5] Group 3: Loan Activity and Market Conditions - Lending activity remained strong in Q2 2025, supported by a resilient labor market and easing inflation, with notable demand for commercial and industrial loans [3] - Mortgage banking revenues are expected to reach $179.6 million, indicating a 3.8% increase from the previous quarter, despite mortgage rates fluctuating in the mid-to-upper 6% range [6] Group 4: Expense Management and Asset Quality - The company aims to keep non-interest expenses at or below $4.2 billion in Q2 2025, despite higher costs related to compensation and employee benefits [10][9] - The Zacks Consensus Estimate for non-performing loans is $1.72 billion, indicating a rise of 1.8% from the prior quarter [10] Group 5: Earnings Expectations - U.S. Bancorp has a positive Earnings ESP of +0.21%, indicating a high likelihood of beating earnings estimates [11] - The consensus estimate for Q2 earnings is $1.07, reflecting a 9.2% increase from the year-ago reported number [12]

MONTREAL (QUEBEC) – TheNewswire - July 15, 2025 - Scandium Canada Ltd. (TSX-V: SCD) (the "Corporation") announces the closing of its previously announced non-brokered private placement of $334,000 subscribed by Taasipitaakin Trust, a trust controlled by the Naskapi Nation of Kawawachikamach. The Taasipitaakin Trust has subscribed to 16,700,000 units of the Corporation (the “Units”) at a price of $0.02 per Unit (the “Offering”). Each Unit consists of one common share of the Corporation (the “Common Shares”) ...

VANCOUVER, BC, July 15, 2025 /PRNewswire/ - Western Copper and Gold Corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) is pleased to provide an update on its Environmental and Socio-economic Effects Statement ("ESE Statement") submission for the Casino Project (the "Project").The ESE Statement incorporates extensive technical work, including environmental and socio-economic baselines studies and assessments. Western is pleased with the progress to date and the level of consultation ach ...

Pineapple Financial Reports Q3 Fiscal 2025 Results: Reduced Losses, Improved Cash Flow, and Sustainable Growth in a Shifting MarketJuly 14, 2025 5:30 PM EDT | Source: Pineapple Financial Inc.Toronto, Ontario--(Newsfile Corp. - July 14, 2025) - Pineapple Financial Inc. (OTC Pink: PAPLF) ("Pineapple" or the "Company"), a leading Canadian mortgage technology and brokerage platform, today announced its unaudited financial results for the three and nine months ended May 31, 2025.In a year defined b ...